Search Clinical Trials
Unknown Status
OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER (External Link)
Current treatment of neurogenic bladder dysfunction (NGB) is limited by the suboptimal results achieved using standard antimuscarinic agents. A prominent role for the actions of alternative transmitters/growth factors in peripheral …